Article
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
JCO precision oncology - 1 Sept 2023
Duska Linda R, Zamarin Dmitriy, Hamilton Erica, Oza Amit, Fleming Gini, Spira Alexander, Yeku Oladapo O, Richardson Debra L, Walling Jackie, Inokuchi Kerry, Matusow Bernice, Bollag Gideon, Swisher Elizabeth M
Abstract excerpt
PURPOSE: The Bromodomain and Extra-Terminal (BET) domain proteins facilitate the development of many human cancers via epigenetic regulation. BET inhibitors may be effective in reversing platinum resistance in ovarian cancer (OC) and may generate synthetic lethality with ARID1A loss. PLX2853 is an orally active, small-molecule inhibitor of BET bromodomain-mediated interactions that exhibits low nanomolar potency...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.